RudaCure Inc. (PDG Yongho Kim), une entreprise mondiale de thérapeutiques de la douleur, a annoncé le 11th that it will present its next-generation traitement de la douleur pipeline research results at the Society for Neuroscience (SfN) Annual Meeting in San Diego, USA on the 19th.
Grâce à cela presentation, RudaCure will disclose données précliniques on its dual-target candidat-médicament innovant that simultaneously modulates TRPV1 and MOR (Mu Opioid Receptor).
Selon RudaCure, the candidate demonstrated excellent efficacité analgésique in divers douleur neuropathique animal models notamment diabetic peripheral neuropathy (DPN) and chemotherapy-induced peripheral neuropathy (CIPN). In the arthrose (OA) model, it showed not only soulagement de la douleur but also tissue damage inhibition and cartilage protective effects.
RudaCure emphasized that this candidate overcomes the fever effets secondaires commonly reported with TRPV1-class drugs and the addiction/tolerance issues of MOR agonists, achieving both efficacy and safety. L'entreprise is accelerating IND-enabling studies for essais cliniques de Phase 1 sur la base de these results.
le PDG Yongho Kim a déclaré : "We will present the innovant potential of our next-generation traitement de la douleur at the world's largest neuroscience conference," adding, "We plan to actively advance global partenariats sur la base de RCI002's differentiated mécanisme d'action."
